Abstract
Autism spectrum disorders (ASD) are a group of pervasive developmental disorders impacting communication, social skills, behavioral interests, and daily functioning. With rates rising to as high as 1 in 80 in the Unites States alone, their impact on children, families, and our society is immense. Despite this, treatment for these conditions is poorly understood, and most have limited empirical support. While ASD can be conceptualized as having system-wide effects in the human body, many of the primary symptoms we associate with these children are clearly related to dysfunction of the central nervous system. While certain brain regions have been shown susceptibility, connectivity across regions of the brain appears to be the primary dysfunction leading to symptoms and developmental delays in these children. Any successful treatment should be able to demonstrate the ability to change and improve these primary effects. Neurofeedback is currently being studied as a noninvasive intervention with the potential to do just that. Empirical evidence is emerging, demonstrating this as a potentially effective and safe form of intervention for ASD. There is also preliminary data suggesting that this intervention may facilitate therapeutic enhancements in brain functioning and connectivity and that the results of treatment may endure even after the therapy has ended. Clearly, more research is needed to demonstrate the efficacy of this intervention, mechanisms that underlie these changes, and studies looking at the duration of enduring effects.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Adams JB, Baral M, Geis E, Mitchell J, Ingram J, Hensley A, Zappia I, Newmark S, Gehn E, Rubin RA, Mitchell K, Bradstreet JJ, El-Dahr J (2009) Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part A—medical results. BMC Clin Pharmacol 9:16
Aman MG, Singh NN, Stewart AW, Field CJ (1985) The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485–491
American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. American Psychiatric Publishing, Washington, DC
Amminger GP, Berger GE, Schäfer MR, Klier C, Friedrich MH, Feucht M (2007) Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 61:551–553
Anderson SR, Avery DL, DiPietro EK, Edwards GL, Christian WP (1987) Intensive home-based early intervention with autistic children. Education and Treatment of Children, 10:352–366
Association for Applied Psychophysiology & Biofeedback (2006). Efficacy: How we rate theefficacy of our treatments or how to know if our treatments actually work. Retrieved February 22, 2006 from http://www.aapb.org/i4a/pages/index.cfm?pageid=3336
Attwood T (1998) Asperger’s syndrome: a guide for parents and professionals. Jessica Kingsley, London
Barnard L, Young AH, Pearson J, Geddes J, O’Brien G (2002) A systematic review of the use of atypical antipsychotics in autism. J Psychopharmacol 16:93–101
Bassett K, Kazanjian A, Green CJ (2000) Autism and Lovaas treatment: a systematic review of effectiveness evidence. British Columbia Office of Health Technology Assessment, Vancouver
Bell JG, Sargent JR, Tocher DR, Dick JR (2000) Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: a characteristic abnormality in neurodevelopmental disorders? Prostaglandins Leukot Essent Fatty Acids 63:21–25
Bell JG, MacKinlay EE, Dick JR, MacDonald DJ, Boyle RM, Glen ACA (2004) Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukot Essent Fatty Acids 71:201–204
Ben-Itzchak E, Zachor DA (2007) The effects of intellectual functioning and autism severity on outcome of early behavioral intervention for children with autism. Res Dev Disabil. 2007 May-Jun; 28(3):287–303
Bernard S, Enayati A, Binstock T, Roger H, Redwood L, McGinnis W (2000) Autism: a unique type of mercury poisoning. Accessed http://whale.to/a/autism7.html
Blaxill MF (2004) What’s going on? The question of time trends in autism. Public Health Rep 119:536–551
Bradstreet JJ, Geier DA, Kartzinel JJ, Adams JB, Geier MR (2003) A case-control study of mercury burden in children with autistic spectrum disorders. J Am Physicians Surg 8:76–79
Cade R, Privette M, Fregly M, Rowland N, Sun Z, Zele V, et al (1999) Autism and schizophrenia: Intestinal disorders. Nutritional Neuroscience, 2:57–72
Centers for Disease Control and Prevention (2009) Prevalence of autism spectrum disorders—autism and developmental disabilities monitoring network, United States, 2006. Morb Mort Wkly Rep 58(SS-10):1–20
Centers for Disease Control and Prevention (2012) Prevalence of autism spectrum disorders—autism and developmental disabilities monitoring network, 14 sites, United States, 2008. Morb Mort Wkly Rep 61(SS-3):1–19
Coben R (2007, September) Autistic spectrum disorder: a controlled study of EEG coherence training targeting social skill deficits. Presented at the 15th annual conference of the international society for neurofeedback and research, San Diego, California.
Coben R (2009) Efficacy of connectivity guided neurofeedback for autistic spectrum disorder: controlled analysis of 75 cases with a 1 to 2 year follow-up. J Neurother 13:81
Coben R, Hudspeth W (2006) Mu-like rhythms in autistic spectrum disorder: EEG analyses and neurofeedback outcome. In: 14th Annual conference of the international society for neuronal regulation, Atlanta
Coben R, Myers TE (2008) Connectivity theory of autism: use of connectivity measures in assessing and treating autistic disorders. J Neurother 12:161–179
Coben R, Padolsky I (2007) Assessment-guided neurofeedback for autistic spectrum disorder. J Neurother 11:5–23
Coben R, Sherlin L, Hudspeth WJ, McKeon K (2009) Connectivity guided EEG biofeedback for autism spectrum disorder: evidence of neurophysiological changes. J Autism Develop Disord (under review).
Coben R, Arns M, Kouijzer MEJ (2010a) Enduring effects of neurofeedback in children. In: Coben R, Evans JR (eds) Neurofeedback and neuromodulation techniques and applications. Academic, London, pp 403–422
Coben R, Linden M, Myers TE (2010b) Neurofeedback for autistic spectrum disorder: a review of the literature. Appl Psychophysiol Biofeedback 35:83–105
Coben R, Chabot RJ, Hirshberg L (2013) EEG analyses in the assessment of autistic disorders. In: Casanova MF, El-Baz AS, Suri JS (eds) Imaging the brain in autism, pp 349–370. Springer, New York
Committee on Children with Disabilities (2001) Technical report: the pediatrician’s role in the diagnosis and management of autistic spectrum disorder in children. Pediatrics 107:e85
Cook EH Jr, Rowlett R, Jaselskis C, Leventhal BL (1992) Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 31:739–745
Couper J (2004) Who should pay for intensive behavioural intervention in autism? A parent’s view. J Paediatr Child Health 40:559–561
Couturier JL, Nicolson R (2002) A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 12:243–248
DeLong GR, Ritch CR, Burch S (2002) Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Dev Med Child Neurol 44:652–659
Demos JN (2005) Getting started with neurofeedback. W.W. Norton, New York, NY
Deprey LJ, Brule N, Widjaja F, Sepheri S, Blank J, Neubrander J, et al (2006) Double-blind placebo-controlled, cross-over trial of subcutaneous methylcobalamin in children with autism: preliminary results. Poster presented at the annual meeting of the American academy of child and adolescent psychiatry, San Diego, CA, October
Doja A, Roberts W (2006) Immunizations and autism: A review of the literature. The Canadian Journal of Neurological Sciences, 33:341–346
Elder JH, Shankar M, Shuster J, Theriaque D, Burns S, Sherrill L (2006) The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. J Autism Dev Disord 36:413–420
Esch BE, Carr JE (2004) Secretin as a treatment for autism: a review of the evidence. J Autism Dev Disord 34:543–556
Ganz ML (2006) The costs of autism. In: Moldin SO, Rubenstein JLR (eds) Understanding autism: from basic neuroscience to treatment. CRC Press, Boca Raton, pp 475–498
Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S, Jacobson JG, Fluoxetine Pediatric OCD Study Team (2001) Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 40:773–779
George MS, Costa D, Kouris K, Ring HA, Ell PJ (1992) Cerebral blood flow abnormalities in adults with infantile autism. J Nerv Ment Dis 180:413–417
Gioia GA, Isquith PK, Guy SC, Kenworthy L (2000) Behavior rating inventory of executive function. Lutz, FL: Psychological Assessment Resources
Gilliam JE (2001) Gilliam asperger’s disorder scale examiner’s manual. Austin, Texas: Pro-Ed.
Golden ZL, Neubauer R, Golden CL, Greene L, Marsh J, Mleko A (2002) Improvement in cerebral metabolism in chronic brain injury after hyperbaric oxygen therapy. Int J Neurosci 112:119–131
Granpeesheh D, Tarbox J, Dixon DR, Wilke AE, Allen MS, Bradstreet JJ (2010) Randomized trial of hyperbaric oxygen therapy for children with autism. Res Autism Spectr Disord 4:268–275
Green VA, Pituch KA, Itchon J, Choi A, O’Reilly M, Sigafoos J (2006) Internet survey of treatments used by parents of children with autism. Research in Developmental Disabilities 27:70–84
Hamilton LM (2000) Facing autism: giving parents reasons for hope and guidance for help. WaterBrook Press, Colorado Springs, CO
Hammond DC (2005) “Neurofeedback with anxiety and affective disorders.” Child and adolescent psychiatric clinics of North America 14.1 (2005): 105
Hediger ML, England LJ, Molloy CA, Yu KF, Manning-Courtney P, Mills JL (2008) Reduced bone cortical thickness in boys with autism or autism spectrum disorder. J Autism Dev Disord 38:848–856
Herbert JD, Sharp IR, Gaudiano BA (2002) Separating fact from fiction in the etiology and treatment of autism. Sci Rev Ment Health Pract 1:23–43
Hill EL (2004) Executive dysfunction in autism. Trends Cogn Sci 8:26–32
Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R (2005) A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30:582–589
Holmes AS (2001) Chelation of mercury for the treatment of autism. Forum on alternative and innovative therapies for children with developmental delays, brain injury and related neurometabolic conditions and disorders. http://www.healing-arts.org/children/holmes.htm. Accessed 30 Mar 2010
Howard JS, Sparkman CR, Cohen HG, Green G, Stanislaw H (2005) A comparison of intensive behavior analytic and eclectic treatments for young children with autism. Research in Developmental Disabilities, 26(4):359–383
Hughes JR, John ER (1999) Conventional and quantitative electroencephalography in psychiatry. J Neuropsychiatry Clin Neurosci 11:190–208
Jarusiewicz B (2002) Efficacy of neurofeedback for children in the autistic spectrum: A pilot study. Journal of Neurotherapy, 6(4):39–49
Jasper HH (1958) The ten–twenty electrode system of the International Federation. Electroencephalogr Clin Neurophysiol, 10:371–5
Jeffrey S Anderson, Nicholas Lange, Alyson Froehlich, Molly B DuBray, T Jason Druzgal, Michael P Froimowitz, Andrew L Alexander, Erin D Bigler, Janet E Lainhart (2010) Decreased left posterior insular activity during auditory language in autism American Journal of Neuroradiology, 31, 1:131–139
Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL, Hechtman L, Hinshaw SP, Pelham WE, Wells KC, Conners CK, Elliott GR, Epstein JN, Hoza B, March JS, Molina BSG, Newcorn JH, Severe JB, Wigal T, Gibbons RD, Hur K (2007) 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 46:989–1002
Jesner OS, Aref-Adib M, Coren E (2007) Risperidone for autism spectrum disorder. Cochrane Database Syst Rev 2007:CD005040
Just MA, Cherkassky VL, Keller TA, Minshew NJ (2004) Cortical activation and synchronization during sentence comprehension in high-functioning autism: evidence of underconnectivity. Brain 127:1811–1821
Kidd PM (2002) Autism, an extreme challenge to integrative medicine, part II: medical management. Altern Med Rev 7:472–499
Kirby D (2005) Evidence of harm: Mercury in vaccines and the autism epidemic: A medical controversy. New York: St. Martin’s Press
Knivsberg A-M, Reichelt K-L, Høien T, Nødland M (2002) A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci 5:251–261
Kouijzer MEJ, de Moor JMH, Gerrits BJL, Buitelaar JK, van Schie HT (2009a) Long-term effects of neurofeedback treatment in autism. Res Autism Spectr Disord 3:496–501
Kouijzer MEJ, de Moor JMH, Gerrits BJL, Congedo M, van Schie HT (2009b) Neurofeedback improves executive functioning in children with autism spectrum disorders. Res Autism Spectr Disord 3:145–162
Kouijzer MEJ, van Schie HT, de Moor JMH, Gerrits BJL, Buitelaar JK (2010) Neurofeedback treatment in autism: preliminary findings in behavioral, cognitive, and neurophysiological functioning. Res Autism Spectr Disord 4:386–399
Lachar D, Gruber CP (2001) Personality inventory for children, second edition. Los Angeles, CA: Western Psychological Services
Linden M, Habib T, Radojevic V (1996) A controlled study of the effects of EEG biofeedback on cognition and behavior of children with attention deficit disorder and learning disabilities. Biofeedback Self Regul 21:35–49
Linden M (2004) Case studies of QEEG map** and neurofeedback with autism. Presented at the 12th Annual Conference of the International Society for Neuronal Regulation, Fort Lauderdale, Florida
Lovaas OI, Koegel R, Simmons JQ, Stevens Long J (1973) Some generalization and follow-up measures on autistic children in behavior therapy. J Appl Behav Anal 6:131–165
Lubar JF (1995) Neurobiological foundation for neurofeedback treatment of attention deficit hyperactivity disorder (ADD/HD). Biofeedback 25(10):4–23
Lubar JF, Swartwood MO, Swartwood JN, O’Donnell PH (1995) Evaluation of the effectiveness of EEG training for ADHD in a clinical setting as measured by TOVA scores, behavioral ratings, and WISC-R performance. Biofeedback&Self-Regulation, 20(1):83–99
Lubar JF (1997) Neurobiological foundation for neurofeedback treatment of attention deficit hyperactivity disorder (ADD/HD). Biofeedback 25(10):4–23
Malone RP, Maislin G, Choudhury MS, Gifford C, Delaney MA (2002) Risperidone treatment in children and adolescents with autism: short-and long-term safety and effectiveness. Journal of the American Academy of Child & Adolescent Psychiatry, 41(2):140–147
Mariani P, Viti MG, Montuori M, La Vecchia A, Cipolletta E, Calvani L, Bonamico M (1998) The gluten-free diet: a nutritional risk factor for adolescents with celiac disease? J Pediatr Gastroenterol Nutr 27:519–523
Martin A, Scahill L, Klin A, Volkmar FR (1999) Higher functioning pervasive developmental disorders: Rates and patterns of psychotropic drug use. Journal of the American Academy of Child and Adolescent Psychiatry, 38:923–931
Martin A, Koenig K, Anderson GM, Scahill L (2003) Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Autism Dev Disord 33:77–85
McAlonan GM, Cheung V, Cheung C, Suckling J, Lam GY, Tai KS, Yip L, Murphy DGM, Chua SE (2005) Map** the brain in autism: a voxel-based MRI study of volumetric differences and intercorrelations in autism. Brain 128:268–276
McCandless J (2005) Children with starving brains: a medical treatment guide for autism spectrum disorders. Bramble Books, Putney
McDougle CJ, Kresch LE, Goodman WK, Naylor ST, Volkmar FR, Cohen DJ, Price LH (1995) A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 152:772–777
McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH (1996) A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001–1008
McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH (1998) Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 18:62–66
McDougle CJ, Kresch LE, Posey DJ (2000) Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 30:427–435
McEachin JJ, Smith TH, Lovaas OI (1993) Long-term outcome for children with autism who received early intensive behavioral treatment. Am J Ment Retard 97:359–391
Monastra VJ, Lynn S, Linden M, Lubar JF, Gruzelier J, La Vaque TJ (2005) Electroencephalographic biofeedback in the treatment of attention-deficit/hyperactivity disorder. Appl Psychophysiol Biofeedback 30:95–114
Montgomery DL, Goldberg J, Amar M, Lacroix VJ, Lecomte JM, Lambert J, Vanasse M, Marois P (1999) Effects of hyperbaric oxygen therapy on children with spastic diplegic cerebral palsy: a pilot project. Undersea Hyperb Med 26:235–242
Mountz JM, Tolbert LC, Lill DW, Katholi CR, Liu H-G (1995) Functional deficits in autistic disorder: characterization by technetium-99 m-HMPAO and SPECT. J Nucl Med 36:1156–1162
Nakano K, Noda N, Tachikawa E, Urano M, Miyuki T, Nakayama T, Sasaki K, Osawa M (2005) A preliminary study of methylcobalamin therapy in autism. J Tokyo Women’s Med Univ 75:64–69
National Institute of Mental Health (2006) Autism spectrum disorders (pervasive developmental disorders). Retrieved 12 Feb 2010 from http://www.nimh.nih.gov/health/publications/autism/complete-index.shtml
Nighoghossian N, Trouillas P, Adeleine P, Salord F (1995) Hyperbaric oxygen in the treatment of acute ischemic stroke. Stroke 26:1369–1372
Oberman LM, Hubbard EM, McCleery JP, Altschuler EL, Ramachandran VS, Pineda JA (2005) EEG evidence for mirror neuron dysfunction in autism spectrum disorders. Cogn Brain Res 24:190–198
Ohnishi T, Matsuda H, Hashimoto T, Kunihiro T, Nishikawa M, Uema T, Sasaki M (2000) Abnormal regional cerebral blood flow in childhood autism. Brain 123:1838–1844
Owley T, Walton L, Salt J, Guter SJ Jr, Winnega M, Leventhal BL, Cook EH Jr (2005) An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 44:343–348
Ozonoff S, Cathcart K (1998) Effectiveness of a home program intervention for young children with autism. J Autism Dev Disord 28:25–32
Pelphrey K, Adolphs R, Morris JP (2004) Neuroanatomical substrates of social cognition dysfunction in autism. Ment Retard Dev Disabil Res Rev 10:259–271
Pineda JA, Hecht E (2009) Mirroring and mu rhythm involvement in social cognition: are there dissociable subcomponents of theory of mind? Biol Psychiatry 80:306–314
Rangaswamy M, Porjez B, Chorlian DB, Wang K, Jones KA, Bauer LO, Rohrbaugh J, O’Connor SJ, Kuperman S, Reich T, Begleiter H (2002) Beta power in the EEG of alcoholics. Biol Psychiatry 52:831–842
Reichelt K (2001, October) Opioid peptides. Paper presented at the defeat autism now conference, San Diego, CA
Reichelt K, Knivsberg AM (2003, October). Why use the gluten-free and casein-free diet in autism and what the results have shown so far: Peptides and autism. Paper presented at the defeat autism now conference, Portland, OR
Research Units on Pediatric Psychopharmacology Autism Network (2005) Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162:1361–1369
Rimland B, Edelson SM (2000) Autism treatment evaluation checklist (ATEC). Autism Research Institute, San Diego
Rippon G, Brock J, Brown CC, Boucher J (2007) Disordered connectivity in the autistic brain: challenges for the ‘new psychophysiology’. Int J Psychophysiol 63:164–172
Rossignol DA, Rossignol LW (2006) Hyperbaric oxygen therapy may improve symptoms in autistic children. Med Hypotheses 67:216–228
Rossignol DA, Rossignol LW, James SJ, Melnyk S, Mumper E (2007) The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study. BMC Pediatr 7:36
Santangelo SL, Tsatsanis K (2005) What is known about autism: genes, brain, and behavior. Am J Pharmacogenomics 5:71–92
Schmitz N, Rubia K, Daly EM, Smith AB, Williams SCR, Murphy DGM (2006) Neural correlates of executive function in autistic spectrum disorders. Biol Psychiatry 59:7–16
Schopler E, Reichler RJ (1971) Parents as cotherapists in the treatment of psychotic children. J Autism Child Schizophr 1:87–102
Schopler E, Reichler RJ, DeVellis RF and Daly K (1980) Toward objective classification of child-hood autism: Childhood Autism Rating Scale (CARS). Journal of Autism and Developmental Disorders 10(1):91–103
Sicile-Kira C (2004) Autism spectrum disorders: the complete guide to understanding autism, Asperger’s syndrome, pervasive developmental disorder, and other ASDs. Berkley Publishing Group, New York, NY
Siegel B (1996) The world of the autistic child: understanding and treating autistic spectrum disorders. Oxford University Press, New York, NY
Sinha Y, Silove N, Williams K (2006) Chelation therapy and autism. BMJ 333:756
Starkstein SE, Vazquez S, Vrancic D, Nanclares V, Manes F, Piven J, Plebst C (2000) SPECT findings in mentally retarded autistic individuals. J Neuropsychiatry Clin Neurosci 12:370–375
Stoller KP (2005) Quantification of neurocognitive changes before, during, and after hyperbaric oxygen therapy in a case of fetal alcohol syndrome. Pediatrics 116:e586–e591
Tansey MA (1993) Ten year stability of EEG biofeedback results for a 10 year old hyperactive boy who failed fourth grade in a class for the perceptually impaired. Biofeedback Self Regul 18:33–44
Thompson M, Thompson L (2003a) The neurofeedback book: an introduction to basic concepts in applied psychophysiology. Association for Applied Psychophysiology and Biofeedback, Wheat Ridge, CO
Thompson L, Thompson M (2003b) Neurofeedback treatment for autistic spectrum disorders: review of 60 cases-principles and outcome. Citation paper presented at the 34th annual meeting of the Association for Applied Psychophysiology and Biofeedback, Jacksonville, FL, March.
Troost PW, Lahuis BE, Steenhuis M-P, Ketelaars CEJ, Buitelaar JK, van Engeland H, Scahill L, Minderaa RB, Hoekstra PJ (2005) Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 44:1137–1144
Vancassel S, Durand G, Barthélémy C, Lejeune B, Martineau J, Guilloteau D, Andrès CR, Chalon S (2001) Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids 65:1–7
Wainwright PE (2002) Dietary essential fatty acids and brain function: a developmental perspective on mechanisms. Proc Nutr Soc 61:61–69
Welchew DE, Ashwin C, Berkouk K, Salvador R, Suckling J, Baron-Cohen S, Bullmore E (2005) Functional disconnectivity of the medial temporal lobe in Asperger’s syndrome. Biol Psychiatry 57:991–998
Yucha C, Montgomery D (2008) Evidence-based practice in biofeedback and neurofeedback. Association for Applied Psychophysiology and Biofeedback, Wheat Ridge
Zilbovicius M, Boddaert N, Belin P, Poline J-B, Remy P, Mangin J-F, Thivard L, Barthélémy C, Samson Y (2000) Temporal lobe dysfunction in childhood autism: a PET study. Am J Psychiatry 157:1988–1993
Zuddas A, Di Martino A, Muglia P, Cianchetti C (2000) Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 10:79–90
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer New York
About this chapter
Cite this chapter
Coben, R. (2013). Neurofeedback for Autistic Disorders: Emerging Empirical Evidence. In: Casanova, M., El-Baz, A., Suri, J. (eds) Imaging the Brain in Autism. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6843-1_6
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6843-1_6
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6842-4
Online ISBN: 978-1-4614-6843-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)